Canadian Agency Recommends Reimbursement for Lilly’s Kisunla
Canada’s drug reimbursement body issued a positive recommendation for Kisunla (donanemab) for early Alzheimer’s disease.
Canada’s drug reimbursement body issued a positive recommendation for Kisunla (donanemab) for early Alzheimer’s disease.